ESHAP and G-CSF for Blood Stem Cell Mobilization in Lymphoma Patients
Author Information
Author(s): Watts M J, Ings S J, Leverett D, MacMillan A, Devereux S, Goldstone A H, Linch D C
Primary Institution: Department of Haematology, University College London
Hypothesis
ESHAP followed by G-CSF is a more effective blood stem cell mobilizing regimen than cyclophosphamide followed by G-CSF for pre-treated lymphoma patients.
Conclusion
ESHAP plus G-CSF is a well-tolerated and superior mobilization regimen for patients with pre-treated lymphoma.
Supporting Evidence
- ESHAP plus G-CSF resulted in a significantly higher percentage of CD34+ cells.
- More patients in the ESHAP group achieved the required CD34+ cell yield with fewer apheresis sessions.
Takeaway
This study found that a treatment called ESHAP helps collect more important blood cells from lymphoma patients than another treatment called cyclophosphamide.
Methodology
Matched pairs analysis comparing ESHAP plus G-CSF to cyclophosphamide plus G-CSF in 78 patients with relapsed or resistant lymphomas.
Participant Demographics
Patients with relapsed or resistant lymphomas.
Statistical Information
P-Value
< 0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website